Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers
Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse…